{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-105825","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.901015+00:00","generated_at":"2026-05-23T02:20:05.800006+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Crofelemer reduces TPN up to 27% in MVID and 12.5% in SBS-IF in proof-of-concept trial","bullets":["Initial POC data shows novel liquid crofelemer reduced parenteral support in MVID and SBS-IF patients by up to 27% and 12.5% respectively.","Data presented at ELITE PED-GI Congress; stool volume/frequency reduced and urine output increased, indicating improved oral absorption.","No approved drugs exist for MVID; crofelemer may qualify for EMA PRIME and FDA Breakthrough Therapy programs.","Company supports three investigator-initiated trials and two placebo-controlled Phase 2 studies for MVID/SBS-IF globally.","Additional POC results from IITs expected throughout 2025; early patient access possible in certain EU countries."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-105825","json":"https://secwatch.observer/filing/0001193125-25-105825.json","markdown":"https://secwatch.observer/filing/0001193125-25-105825.md","text":"https://secwatch.observer/filing/0001193125-25-105825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525105825/0001193125-25-105825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525105825/d935544d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:20:05.800006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}